Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Negrao MV, et al. Among authors: delasos l. Cancer Discov. 2023 Jul 7;13(7):1556-1571. doi: 10.1158/2159-8290.CD-22-1420. Cancer Discov. 2023. PMID: 37068173 Free PMC article.
Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.
Odintsov I, Mattar MS, Lui AJW, Offin M, Kurzatkowski C, Delasos L, Khodos I, Asher M, Daly RM, Rekhtman N, de Stanchina E, Ganji G, Ladanyi M, Somwar R. Odintsov I, et al. Among authors: delasos l. J Thorac Oncol. 2021 Jul;16(7):1149-1165. doi: 10.1016/j.jtho.2021.03.013. Epub 2021 Apr 8. J Thorac Oncol. 2021. PMID: 33839363 Free PMC article.
RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
Hayashi T, Odintsov I, Smith RS, Ishizawa K, Liu AJW, Delasos L, Kurzatkowski C, Tai H, Gladstone E, Vojnic M, Kohsaka S, Suzawa K, Liu Z, Kunte S, Mattar MS, Khodos I, Davare MA, Drilon A, Cheng E, Stanchina E, Ladanyi M, Somwar R. Hayashi T, et al. Among authors: delasos l. Dis Model Mech. 2020 Dec 14;14(2):dmm047779. doi: 10.1242/dmm.047779. Online ahead of print. Dis Model Mech. 2020. PMID: 33318047 Free PMC article.
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Drilon A, Bergagnini I, Delasos L, Sabari J, Woo KM, Plodkowski A, Wang L, Hellmann MD, Joubert P, Sima CS, Smith R, Somwar R, Rekhtman N, Ladanyi M, Riely GJ, Kris MG. Drilon A, et al. Among authors: delasos l. Ann Oncol. 2016 Jul;27(7):1286-91. doi: 10.1093/annonc/mdw163. Epub 2016 Apr 7. Ann Oncol. 2016. PMID: 27056998 Free PMC article.
The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions.
Odintsov I, Lui AJW, Sisso WJ, Gladstone E, Liu Z, Delasos L, Kurth RI, Sisso EM, Vojnic M, Khodos I, Mattar MS, de Stanchina E, Leland SM, Ladanyi M, Somwar R. Odintsov I, et al. Among authors: delasos l. Clin Cancer Res. 2021 Jun 1;27(11):3154-3166. doi: 10.1158/1078-0432.CCR-20-3605. Epub 2021 Apr 6. Clin Cancer Res. 2021. PMID: 33824166 Free PMC article.
Primary Bone Lymphoma: A Case Series and Review of Literature.
Bindal P, Desai A, Delasos L, Mulay S, Vredenburgh J. Bindal P, et al. Among authors: delasos l. Case Rep Hematol. 2020 Apr 10;2020:4254803. doi: 10.1155/2020/4254803. eCollection 2020. Case Rep Hematol. 2020. PMID: 32328322 Free PMC article.
18 results